07:17 AM EDT, 10/14/2025 (MT Newswires) -- GSK (GSK) said Tuesday that the China National Medical Products Administration has approved Shingrix, its Recombinant Zoster Vaccine for the prevention of shingles, or herpes zoster, in adults aged 18 years and over.

The company said its application was informed by six clinical trials in patients aged 18 years and up who had recently undergone blood-forming cell or stem cell transplantation, kidney transplant, or have blood cancer, solid tumor, or HIV.

GSK said shingles poses a significant health burden, with six million cases reported in China each year.